Letters & Comments

NHC Comments on ICER Unsupported Price Increase Assessment
(Wednesday, February 13, 2019 04:30 PM)
NHC Comments on Framework for a Real-World Evidence Program; Availability
(Thursday, February 7, 2019 11:00 AM)
NHC Comments on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out of Pocket Expenses
(Friday, January 25, 2019 06:30 PM)
NHC Comments on Patient Engagement in Medical Device Clinical Trials Discussion Document
(Tuesday, January 8, 2019 04:30 PM)
NHC Comments on Advance Notice of Proposed Rulemaking: International Price Index Model for Medicare Part B Drugs
(Monday, December 31, 2018 01:30 PM)
NHC Letter on State Relief and Empowerment Waivers
(Monday, December 24, 2018 01:30 PM)
NHC Comments on Patient-Focused Drug Development Guidance: Methods To Identify What Is Important to Patients and Select, Develop, or Modify Fit-for-Purpose Clinical Outcome Assessments
(Friday, December 14, 2018 02:30 PM)
NHC Comments on Accountable Care Organizations Pathways to Success
(Tuesday, October 16, 2018 02:15 PM)
NHC Comments on FDA Standard Core Clinical Outcome Assessments and Endpoints
(Monday, October 15, 2018 12:00 PM)
Letter to Secretary Azar on the Administration's Step Therapy Policy
(Wednesday, September 26, 2018 05:00 PM)
NHC Comments on Medicare Program: Proposed Changes to Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs
(Wednesday, September 26, 2018 12:00 PM)
NHC Comments on the FDA’s Draft Guidance on Patient-Focused Drug Development: Collecting Comprehensive and Representative Input
(Tuesday, September 11, 2018 04:30 PM)
NHC Comments on the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
(Monday, July 16, 2018 05:00 PM)
NHC Comments on Proposed Rule, Short-Term, Limited-Duration Insurance
(Monday, April 23, 2018 (All day))
Letter to Congress Expressing Concern with Short-Term Limited Duration Plans
(Wednesday, April 18, 2018 (All day))
NHC Comments on PFDD Guidance 1 – Collecting Comprehensive and Representative Input
(Friday, February 16, 2018 (All day))
NHC Letter on Creating and Restoring Equal Access to Equivalent Samples Act of 2017 (CREATES Act)
(Friday, February 2, 2018 (All day))
NHC Comments on Centers for Medicare & Medicaid Services: Innovation Center New Direction
(Monday, November 20, 2017 (All day))
NHC Comments on Administering the Hatch-Waxman Amendments: Ensuring a Balance between Innovation and Access
(Friday, November 17, 2017 (All day))
120+ Patient Advocates Urge Congress to Reauthorize FDA User Fee Agreements
(Friday, May 5, 2017 (All day))

Pages